Adenosine prevents isoprenaline-induced cardiac contractile and electrophysiological dysfunction

Yangzhen Shao1, Björn Redfors, Lillemor Mattson-Hultén

  • 1Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Insights

Adenosine prevents cardiac dysfunction and reduces lipid accumulation in a mouse model of stress-induced cardiomyopathy. This study highlights adenosine

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Excessive catecholamines contribute to cardiac dysfunction in various diseases.
  • Stress-induced cardiomyopathy, linked to high morbidity and mortality, involves catecholamine excess.
  • Previous research showed isoprenaline induces reversible left ventricular dysfunction in mice.

Purpose of the Study:

  • To investigate the potential of adenosine in preventing cardiac dysfunction in a mouse model of stress-induced cardiomyopathy.
  • To evaluate the effects of adenosine on myocardial fibrosis and intracellular lipid accumulation.
  • To assess adenosine's impact on electrophysiological parameters in cardiomyocytes.

Main Methods:

  • Male C57BL/6 mice were injected with isoprenaline and randomized to adenosine or saline treatment.
  • Cardiac function was assessed using echocardiography at multiple time points post-injection.
  • Myocardial fibrosis and intracellular lipid accumulation were quantified, along with electrophysiological studies in HL1 cells.

Main Results:

  • Adenosine treatment significantly improved global and regional cardiac function compared to saline.
  • Adenosine-treated mice showed reduced intracellular lipid accumulation and no significant myocardial fibrosis.
  • Adenosine-treated HL1 cells maintained electrophysiological function and exhibited less lipid accumulation.

Conclusions:

  • Adenosine effectively attenuates isoprenaline-induced cardiac dysfunction in a mouse model.
  • Adenosine demonstrates protective effects against myocardial fibrosis and lipid accumulation.
  • Adenosine shows promise as a therapeutic agent for stress-induced cardiomyopathy.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...